University of Brighton

DALLAS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Prof. Paul Chadwick as Executive Vice President of the Company’s United Kingdom subsidiary. Prof. Chadwick is an experienced clinical scientist and wound care key opinion leader (KOL) with an impressive body of work including a substantial and impactful publication record, particularly in the domain of diabetic wound management. He will be responsible for the international market expansion of the Company’s DeepView® wound imaging technology in the United Kingdom, Europe, Middle East and Africa (EMEA), all of which are geographic areas where Prof. Chadwick has extensive clinical networks, significant experience and has enjoyed previous successes. “Paul brings over fifteen years of invaluable expertise in the medical devices and technology sectors to our team. The Royal College of Podiatry is an extremely prestigious and important organization where Paul most recently served for over six years in senior executive capacities, including CEO. We are highly confident that his addition will significantly enhance our efforts in advancing the widespread adoption of the DeepView® System,” said Niko Pagoulatos, the Company’s COO. “Spectral AI continues to strengthen its leadership team and Paul’s experience in diabetic foot ulcers and clinical wound management will contribute to our growth and enhance our capacity to innovate.” Prof. Chadwick’s impressive journey stretches across clinical, academic and business disciplines. In his previous roles at the Royal College of Podiatry, Prof. Chadwick led all the clinical, educational and financial aspects of the organization. In addition, he has held multiple leadership positions such as consultant podiatrist at The National Health Service (NHS), and Managing Director at Curativo Wound Care Consultancy, where he has served companies such as 3M, Molnlycke Health Care, Smith & Nephew, Advancis, Thornton & Ross, Essity and many others. In his capacity as a prominent authority in wound care, Prof. Chadwick fulfills critical roles on advisory boards and exemplifies best practices in the field. Furthermore, he generously imparts his knowledge as an adjunct professor at Birmingham City University, where he teaches in the Health and Life Sciences Department. Prof. Chadwick said, “Coming from a traditional wound care background with an emphasis on DFU and other chronic wounds, and having collaborated with leading commercial organizations in the wound care arena at a national and global level, with a focus on EMEA, I am delighted to contribute to Spectral AI’s mission and success, and I believe that the DeepView® System represents the future of wound healing management. As we move forward, this technology has the potential to transform patient wound care at multiple levels.” Prof. Chadwick earned his Ph.D. with a thesis on aspects of painful diabetic neuropathy at the University of Salford. He earned his M.Sc. with a focus on foot ulceration from Manchester Metropolitan University and holds an undergraduate degree in Science Honors from the University of Brighton. About Spectral AI Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView®, visit www.spectral-ai.com. Forward Looking Statements Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements. Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Contacts: Investors:Spectral AI, Inc.Christine Marks VP Marketing and Commercialization ir@spectral-ai.com The Equity Group Devin Sullivan Managing Director dsullivan@equityny.com Conor Rodriguez Analyst crodriguez@equityny.com Media: Russo Partners David Schull Russo Partners (858) 717-2310 david.schull@russopartnersllc.com Guillermo Ruiz, M.D., Ph.D. Russo Partners (646) 218-4604 guillermo.ruiz@russopartnersllc.com

Effective September 5, 2023, Idorsia Pharmaceuticals U.S. Inc. to be led by Tausif ('Tosh') Butt who brings more than 20 years of pharmaceutical leadership experience. Patricia "Patty" Torr to step down to pursue other opportunities. RADNOR, Pa., Aug. 31, 2023 /PRNewswire/ -- Idorsia Pharmaceuticals U.S. Inc. today announced that Tausif ('Tosh') Butt will join the organization as the new President and General Manager on September 5, 2023. Tosh succeeds Patty Torr who is leaving Idorsia to pursue other opportunities. Jean-Paul Clozel, MD and Chief Executive Officer of Idorsia commented: "Patty joined Idorsia in March 2020 as the first U.S. commercial employee, establishing the U.S. organization and preparing for our first product launch – both major undertakings which were made even more complicated during the COVID-19 pandemic. Under Patty's leadership, the U.S. team has driven demand and product adoption for QUVIVIQ and made progress in securing reimbursement. I would like to thank Patty for leaving Idorsia U.S. with a solid foundation to build upon and I wish her all the best in her future endeavors." Jean-Paul Clozel continued: "Tosh has a rich expertise spanning complex operations, and the commercialization of products across different disease areas and medical settings. I believe he will bring the approach we need for the U.S. organization's current priorities, and his reputation for delivering results is impressive. I'm very happy with the confidence Tosh is placing in Idorsia, and our approach to ensuring long-term sustainability of the company." Tosh Butt, BSc, MSc, commented: "I have not taken the decision to join Idorsia lightly. I've spoken to the executive team and looked at their strategy for the future of Idorsia – I am truly excited to work on a product with such potential as QUVIVIQ and at a company with the ability to innovate. I am certain that I bring valuable experience and can lead the U.S. team to commercial success. I'm looking forward to gathering the team together and starting to face our challenges head-on from day one." About Tosh Butt Tosh Butt is a highly accomplished industry executive with more than 20 years of pharmaceutical leadership experience. Prior to joining Idorsia, Tosh Butt served as Executive Vice President and Chief Operating Officer of ChemoCentryx, Inc., a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, which was acquired by Amgen in October 2022. At ChemoCentryx, Tosh built the commercial, market access, medical affairs, and tech ops functions, securing regulatory approval for the company's first product in the US, Canada, EU, and Japan, and successfully launching the product in the rare disease space. Before that, Tosh was Senior Vice President of Latin America for AstraZeneca, where he led a team of more than 2,000 people, including five country presidents. Serving in leadership roles at AstraZeneca for more than six years – in marketing, sales, and market access – across the company's primary care, biologics and vaccines, and oncology business lines, Tosh launched products in both primary and specialty care, including the company's first biologic. Prior to this, he held several marketing and sales leadership roles in the United States, United Kingdom and France with GlaxoSmithKline and Sanofi. Tosh Butt holds both US and British citizenship and has a Bachelor's degree in Pharmacy from the University of Brighton, UK, and an MSc in Management from Imperial College, University of London. Notes to the editor About Idorsia US Idorsia US, an affiliate of Idorsia, is reaching out for more – we have more ideas, we see more opportunities, and we want to help more patients. To achieve this, we will help develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. With commercial operations based outside of Philadelphia, PA, one of densest communities of life science talent in the world, we are helping to realize the company's ambition of bringing innovative medicines from bench to bedside. Our goal is to build a commercial footprint that will deliver Idorsia's deep pipeline of products from its R&D engine to the US market – with the potential to change the lives of many patients. For further information, please contact US Media Christopher Clark Senior Director, US Head of Communications Idorsia Pharmaceuticals US, 100 Matsonford Road, Radnor, PA 19087 +1 (215) 421 4887 [email protected] Global Investors & Media Andrew C. Weiss Senior Vice President, Head of Investor Relations & Corporate Communications Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil +41 58 844 10 10 [email protected] [email protected] The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. SOURCE Idorsia Pharmaceuticals U.S.

Credit: Getty images/ Westend61 For a long time, aging biology and research have been enigmatic areas that biotechs hoped to capitalise on due to their market potential. Whether one refers to such research as “longevity”, “anti-aging” or “extending healthspan”, it is clear this area has evolved massively over the last few years with more scientists now eager to get drugs in this area from bench to bedside. However, struggles to prove to regulators the validity of or need for drugs in this realm still serve as a major barrier to success. Free Report How is the Biopharmaceutical industry evolving? 2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to: Benchmark the impact of major themes on the Biopharmaceutical industry. Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents. Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success. By GlobalData Submit Country Code UK (+44) USA (+1) Algeria (+213) Andorra (+376) Angola (+244) Anguilla (+1264) Antigua & Barbuda (+1268) Argentina (+54) Armenia (+374) Aruba (+297) Australia (+61) Austria (+43) Azerbaijan (+994) Bahamas (+1242) Bahrain (+973) Bangladesh (+880) Barbados (+1246) Belarus (+375) Belgium (+32) Belize (+501) Benin (+229) Bermuda (+1441) Bhutan (+975) Bolivia (+591) Bosnia Herzegovina (+387) Botswana (+267) Brazil (+55) Brunei (+673) Bulgaria (+359) Burkina Faso (+226) Burundi (+257) Cambodia (+855) Cameroon (+237) Canada (+1) Cape Verde Islands (+238) Cayman Islands (+1345) Central African Republic (+236) Chile (+56) China (+86) Colombia (+57) Comoros (+269) Congo (+242) Cook Islands (+682) Costa Rica (+506) Croatia (+385) Cuba (+53) Cyprus North (+90392) Cyprus South (+357) Czech Republic (+42) Denmark (+45) Djibouti (+253) Dominica (+1809) Dominican Republic (+1809) Ecuador (+593) Egypt (+20) El Salvador (+503) Equatorial Guinea (+240) Eritrea (+291) Estonia (+372) Ethiopia (+251) Falkland Islands (+500) Faroe Islands (+298) Fiji (+679) Finland (+358) France (+33) French Guiana (+594) French Polynesia (+689) Gabon (+241) Gambia (+220) Georgia (+7880) Germany (+49) Ghana (+233) Gibraltar (+350) Greece (+30) Greenland (+299) Grenada (+1473) Guadeloupe (+590) Guam (+671) Guatemala (+502) Guinea (+224) Guinea - Bissau (+245) Guyana (+592) Haiti (+509) Honduras (+504) Hong Kong (+852) Hungary (+36) Iceland (+354) India (+91) Indonesia (+62) Iran (+98) Iraq (+964) Ireland (+353) Israel (+972) Italy (+39) Jamaica (+1876) Japan (+81) Jordan (+962) Kazakhstan (+7) Kenya (+254) Kiribati (+686) Korea North (+850) Korea South (+82) Kuwait (+965) Kyrgyzstan (+996) Laos (+856) Latvia (+371) Lebanon (+961) Lesotho (+266) Liberia (+231) Libya (+218) Liechtenstein (+417) Lithuania (+370) Luxembourg (+352) Macao (+853) Macedonia (+389) Madagascar (+261) Malawi (+265) Malaysia (+60) Maldives (+960) Mali (+223) Malta (+356) Marshall Islands (+692) Martinique (+596) Mauritania (+222) Mayotte (+269) Mexico (+52) Micronesia (+691) Moldova (+373) Monaco (+377) Mongolia (+976) Montserrat (+1664) Morocco (+212) Mozambique (+258) Myanmar (+95) Namibia (+264) Nauru (+674) Nepal (+977) Netherlands (+31) New Caledonia (+687) New Zealand (+64) Nicaragua (+505) Niger (+227) Nigeria (+234) Niue (+683) Norfolk Islands (+672) Northern Marianas (+670) Norway (+47) Oman (+968) Palau (+680) Panama (+507) Papua New Guinea (+675) Paraguay (+595) Peru (+51) Philippines (+63) Poland (+48) Portugal (+351) Puerto Rico (+1787) Qatar (+974) Reunion (+262) Romania (+40) Russia (+7) Rwanda (+250) San Marino (+378) Sao Tome & Principe (+239) Saudi Arabia (+966) Senegal (+221) Serbia (+381) Seychelles (+248) Sierra Leone (+232) Singapore (+65) Slovak Republic (+421) Slovenia (+386) Solomon Islands (+677) Somalia (+252) South Africa (+27) Spain (+34) Sri Lanka (+94) St. Helena (+290) St. Kitts (+1869) St. Lucia (+1758) Sudan (+249) Suriname (+597) Swaziland (+268) Sweden (+46) Switzerland (+41) Syria (+963) Taiwan (+886) Tajikstan (+7) Thailand (+66) Togo (+228) Tonga (+676) Trinidad & Tobago (+1868) Tunisia (+216) Turkey (+90) Turkmenistan (+7) Turkmenistan (+993) Turks & Caicos Islands (+1649) Tuvalu (+688) Uganda (+256) Ukraine (+380) United Arab Emirates (+971) Uruguay (+598) Uzbekistan (+7) Vanuatu (+678) Vatican City (+379) Venezuela (+58) Vietnam (+84) Virgin Islands - British (+1284) Virgin Islands - US (+1340) Wallis & Futuna (+681) Yemen (North)(+969) Yemen (South)(+967) Zambia (+260) Zimbabwe (+263) Country UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo Submit By clicking the Download Free Report button, you accept the terms and conditions and acknowledge that your data will be used as described in the GlobalData privacy policy By downloading this Report, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services. Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Thank you. Please check your email to download the Report. In an email to Pharmaceutical Technology, an aging researcher, Dr. Ronald Kohanski, defined aging as “a progressive accumulation of functional deficits, meaning that biological systems do not function as well later in life as they do earlier in life.” Kohanski is the director of the Division of Aging Biology (DAB) at the National Institute on Aging (NIA), a division of the US National Institutes of Health. Kohanski emphasised that researchers at the institute approach their work by focusing on “healthy aging” rather than “anti-aging.” This is often studied using aging clocks, which measure biological age by evaluating different aging processes. Currently, most drugs being investigated for their healthy aging or anti-aging properties are being repurposed from readily accessible FDA-approved drugs. For example, in the Targeting Aging with Metformin (TAME) Trial , a series of six-year studies, the diabetes drug metformin will be studied for its effects in preventing age-related conditions such as cardiovascular disease, cancer, impaired cognition, and mortality. Dr. Nir Barzilai, the scientific director for TAME and the director of the Institute for Aging Research at the Albert Einstein College of Medicine, New York, says projects like the TAME trial could be what regulators need to see to prove the validity of clinical trials in this area. Based on preclinical research for their impact on aging, well-known drugs like metformin and rapamycin are already being considered for off-label usage, due to their accepted safety profile and cost-effectiveness. Barzilai hopes that the well-established profile of the drug may allow the FDA to accept the trial more easily and then other aging-related studies can follow. Aging-related pharmaceuticals and research also need to overcome the barrier of sensational and negative press. “Right now, unfortunately, the aging clocks have gotten a bad name, because there’s been this rush of direct-to-consumer companies that are selling completely unvalidated things to people,” says Dr. Matt Kaeberlein, director of the Healthy Aging and Longevity Research Institute, at University of Washington, Seattle. Concerns exist that headlines touting claims such as “anti-inflammatory drugs turn back time…” and referring to research as a “search for eternal youth” may misrepresent the aims of the field. Kaeberlein says such research is having a harmful effect on the regulatory side: “The FDA is watching this, and they can see it’s not scientific.” What is aging clinical research? The geroscience industry mostly centres aging research around the “hallmarks of aging.” There are eight hallmarks that define aging , including stem cell dysfunction, inflammation, senescence, and more. The National Cancer Institute (NCI) defines senescence as the “process by which a cell ages and permanently stops dividing but does not die.” Within these hallmarks, different laboratories have found distinct ways to track and quantify aging. Kohanski highlights that repurposing the drugs like Novartis’ Sprycel (dasatinib) and the flavonoid quercetin to treat cellular senescence “show significant promise.” Traditionally, people are prescribed Sprycel and quercetin for chronic myeloid leukaemia and anti-inflammatory effects, respectively. Dr. Richard Faragher, a professor of biogerontology at the University of Brighton, is looking at a new way to target senescence with a class of small molecules called resveralogues that aim to reverse senescence in cells. In his studies, Faragher uses biomarkers to track changes in aging clocks. However, Kaeberlein explains, “The challenge with that is I think we’re pretty far away from the FDA recognizing those biomarkers as true surrogate endpoints for clinical trial.” This regulatory issue coupled with others has hindered the clinical development of drugs in the field. At Kaeberlein’s lab, studies track effects on aging through an approach that is largely focused on genetics, modifying different genes to figure out what affects healthspan and lifespan. “About 2,000 small molecules have been tested for their effects on lifespan,” says Kaeberlein. These are listed in the publicly available DrugAge Database. Furthermore, Kaeberlein explains that, as aging is such a broad area, many studies look at composite endpoints. Thus, rather than looking at a primary endpoint for one disease or condition, studies like the TAME trial may concentrate on multiple measures. Others have chosen to focus on the functional measures of aging. An example of this is Dr. Ilaria Bellantuono’s lab, which is investigating medicines for frailty, which she describes “as an accumulation of deficits” in organ function. Bellantuono is the co-director of the Healthy Lifespan Institute at the University of Sheffield. Barriers to regulatory success Experts are currently debating the key to success for new healthy aging drugs as some logistical issues hold the field back. For example, Kaeberlein says that the length of a clinical study to investigate an entire lifespan is often dismissed for not being cost-effective. Thus far, lifespan studies have only been possible in animals. Kaeberlein is working on a trial investigating rapamycin’s effects on the healthspan of 580 pet dogs. Such issues may have caused hesitance in some drug regulators. Barzilai predicts that in the future, the FDA will develop an “easier indication” to define aging in clinical research and this may give studies more of a platform to progress through the regulatory system. “Then we’ll extend the use to longevity,” he says. However, many see possible flaws with this solution. Bellantuono worries that labeling aging as a disease indication could be “agist” and would have social implications. Bellantuono prefers to reference aging as a risk factor for disease, saying, “if you decelerate aging, you have the [potential] of reducing the chance you’re going to get multiple sclerosis or dementia, or cardiovascular disease.” The UK also faces similar regulatory challenges as some public health officials and drug regulators are slow to collaborate with pharmaceutical researchers on aging-related work. Bellantuono says this may be because they need to consider cost-effectiveness and whether the preventive nature of drugs in the field impacts age-related diseases significantly enough to warrant approval. Barzilai explains that some biotechs are looking at developing drugs for age-related diseases and repurposing them specifically to treat aging, which makes funding for clinical trials easier. Kaeberlein says efforts to label aging as an indication may be misguided. “It’s not going to change the equation at all in terms of getting a drug approved by the FDA. You still need to have the endpoints that are quantitative, measurable, and tell us something about quantity or quality of life for people,” he says. Another way to view this would be to consider biological aging as the greatest risk factor for every age-related disease, and that would include almost all the major causes of death and disability in developed countries. “If you can get [the FDA] to recognize that then I think there might be an opportunity for what would fall under the umbrella of a fast track for clinical trials that target the biology of aging,” says Kaeberlein. He goes on to say that this might incentivize more pharmaceutical companies to develop drugs that target the biology of aging. “The incentive from the FDA’s perspective would be the possible larger effect size on multiple age-related diseases compared to that of drugs currently being developed,” he says. Nonetheless, Faragher has high hopes for the field’s prospects, having coordinated ten UK Research and Innovation’s (UKRI)-funded networks looking at improving healthspan. Faragher is optimistic that regulators will get on board with actively accepting healthy aging pharmaceuticals into healthcare, predicting that in the next century this indication may receive a rush of activity. He says, “The dam hasn’t broken, but there are some very big cracks in it…. We need to act decisively now and start to do the research really diligently.” Free Report How is the Biopharmaceutical industry evolving? 2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to: Benchmark the impact of major themes on the Biopharmaceutical industry. Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents. Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success. By GlobalData Submit Country Code UK (+44) USA (+1) Algeria (+213) Andorra (+376) Angola (+244) Anguilla (+1264) Antigua & Barbuda (+1268) Argentina (+54) Armenia (+374) Aruba (+297) Australia (+61) Austria (+43) Azerbaijan (+994) Bahamas (+1242) Bahrain (+973) Bangladesh (+880) Barbados (+1246) Belarus (+375) Belgium (+32) Belize (+501) Benin (+229) Bermuda (+1441) Bhutan (+975) Bolivia (+591) Bosnia Herzegovina (+387) Botswana (+267) Brazil (+55) Brunei (+673) Bulgaria (+359) Burkina Faso (+226) Burundi (+257) Cambodia (+855) Cameroon (+237) Canada (+1) Cape Verde Islands (+238) Cayman Islands (+1345) Central African Republic (+236) Chile (+56) China (+86) Colombia (+57) Comoros (+269) Congo (+242) Cook Islands (+682) Costa Rica (+506) Croatia (+385) Cuba (+53) Cyprus North (+90392) Cyprus South (+357) Czech Republic (+42) Denmark (+45) Djibouti (+253) Dominica (+1809) Dominican Republic (+1809) Ecuador (+593) Egypt (+20) El Salvador (+503) Equatorial Guinea (+240) Eritrea (+291) Estonia (+372) Ethiopia (+251) Falkland Islands (+500) Faroe Islands (+298) Fiji (+679) Finland (+358) France (+33) French Guiana (+594) French Polynesia (+689) Gabon (+241) Gambia (+220) Georgia (+7880) Germany (+49) Ghana (+233) Gibraltar (+350) Greece (+30) Greenland (+299) Grenada (+1473) Guadeloupe (+590) Guam (+671) Guatemala (+502) Guinea (+224) Guinea - Bissau (+245) Guyana (+592) Haiti (+509) Honduras (+504) Hong Kong (+852) Hungary (+36) Iceland (+354) India (+91) Indonesia (+62) Iran (+98) Iraq (+964) Ireland (+353) Israel (+972) Italy (+39) Jamaica (+1876) Japan (+81) Jordan (+962) Kazakhstan (+7) Kenya (+254) Kiribati (+686) Korea North (+850) Korea South (+82) Kuwait (+965) Kyrgyzstan (+996) Laos (+856) Latvia (+371) Lebanon (+961) Lesotho (+266) Liberia (+231) Libya (+218) Liechtenstein (+417) Lithuania (+370) Luxembourg (+352) Macao (+853) Macedonia (+389) Madagascar (+261) Malawi (+265) Malaysia (+60) Maldives (+960) Mali (+223) Malta (+356) Marshall Islands (+692) Martinique (+596) Mauritania (+222) Mayotte (+269) Mexico (+52) Micronesia (+691) Moldova (+373) Monaco (+377) Mongolia (+976) Montserrat (+1664) Morocco (+212) Mozambique (+258) Myanmar (+95) Namibia (+264) Nauru (+674) Nepal (+977) Netherlands (+31) New Caledonia (+687) New Zealand (+64) Nicaragua (+505) Niger (+227) Nigeria (+234) Niue (+683) Norfolk Islands (+672) Northern Marianas (+670) Norway (+47) Oman (+968) Palau (+680) Panama (+507) Papua New Guinea (+675) Paraguay (+595) Peru (+51) Philippines (+63) Poland (+48) Portugal (+351) Puerto Rico (+1787) Qatar (+974) Reunion (+262) Romania (+40) Russia (+7) Rwanda (+250) San Marino (+378) Sao Tome & Principe (+239) Saudi Arabia (+966) Senegal (+221) Serbia (+381) Seychelles (+248) Sierra Leone (+232) Singapore (+65) Slovak Republic (+421) Slovenia (+386) Solomon Islands (+677) Somalia (+252) South Africa (+27) Spain (+34) Sri Lanka (+94) St. Helena (+290) St. Kitts (+1869) St. Lucia (+1758) Sudan (+249) Suriname (+597) Swaziland (+268) Sweden (+46) Switzerland (+41) Syria (+963) Taiwan (+886) Tajikstan (+7) Thailand (+66) Togo (+228) Tonga (+676) Trinidad & Tobago (+1868) Tunisia (+216) Turkey (+90) Turkmenistan (+7) Turkmenistan (+993) Turks & Caicos Islands (+1649) Tuvalu (+688) Uganda (+256) Ukraine (+380) United Arab Emirates (+971) Uruguay (+598) Uzbekistan (+7) Vanuatu (+678) Vatican City (+379) Venezuela (+58) Vietnam (+84) Virgin Islands - British (+1284) Virgin Islands - US (+1340) Wallis & Futuna (+681) Yemen (North)(+969) Yemen (South)(+967) Zambia (+260) Zimbabwe (+263) Country UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo Submit By clicking the Download Free Report button, you accept the terms and conditions and acknowledge that your data will be used as described in the GlobalData privacy policy By downloading this Report, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services. Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Thank you. Please check your email to download the Report.